Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Alunacedase alfa - Apeiron Biologics

Next Previous
Drug Profile

Alunacedase alfa - Apeiron Biologics

Alternative Names: APN-01; GSK-2586881; Recombinant-human-soluble-angiotensin-converting-enzyme-2-Apeiron-Biologics; rhACE2; rhACE2-Apeiron-Biologics

Latest Information Update: 28 Nov 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Apeiron Biologics
  • Developer Apeiron Biologics; GlaxoSmithKline; University of British Columbia
  • Class Anti-ischaemics; Antihypertensives; Antineoplastics; Antivirals; Cardiovascular therapies; Heart failure therapies; Recombinant proteins
  • Mechanism of Action ACE stimulants; Virus internalisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Acute lung injury; Adult respiratory distress syndrome; COVID 2019 infections; Pulmonary arterial hypertension
  • Discontinued Cancer; Diabetic nephropathies; Heart failure; Hypertension; Myocardial infarction

Most Recent Events

  • 28 Nov 2024 No recent reports of development identified for phase-I development in COVID-2019-infections(In volunteers) in Austria (Inhalation, Liquid)
  • 03 Nov 2022 Alunacedase alfa - Apeiron Biologics is available for licensing as of 03 Nov 2022. https://www.invios.com/
  • 03 Nov 2022 Adverse events and pharmacodynamics data from a phase I trial in COVID-2019 infections (In volunteers) released by APEIRON Respiratory Therapies

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top